MoneyWorks4Me

Alembic Pharmaceuticals informs about disclosure

11 Sep 2026 Evaluate
Alembic Pharmaceuticals has informed that the company has successfully completed an unannounced onsite Bioequivalence inspection conducted by United States Food and Drug Administration (‘USFDA’) at the Company’s Bioequivalence Facility located in Vadodara, Gujarat, with no Form 483 observations. The unannounced onsite USFDA Bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..